Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

Cell and Gene Therapy Insights 2023; 9(5), 809


Published: 25 August 2023
Andrew Mancini

Watch the video or view the poster to learn about: 

  • How choosing a clinically-validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing.
  • The MaxCyte GTx™a clinically-validated electroporation platform optimized for cell therapy manufacturing.
  • How to address key risk factors during the cell therapy manufacturing process, such as process variability, complexity, and product yield.
  • The importance of robust, expert technical and regulatory support in enhancing risk mitigation